Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design
Study context
- Population
- Adults aged 40–80 years with T2DM, HbA1c ≥ 7.0% to ≤ 10.5% and ≥20% stenosis in a major epicardial vessel on CCTA
- Planned comparison
- Tirzepatide vs placebo
- Primary endpoint
- Progression of atherosclerotic plaque by multidetector computed tomography angiography (MDCTA)
- Follow-up
- 1 year
Methodological detailsrationale and design, double-blind, placebo-controlled, prospective, multicentre, phase IV, Quarterly visits for safety assessments and labs; repeat CCTA at 1 year
- Rationale and design
- Double-blind
- Placebo-controlled
- Prospective
- Multicentre
- Phase IV
- Quarterly visits for safety assessments and labs; repeat CCTA at 1 year
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design. Am Heart J. Published 24 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →